Brain Disorders

Oct 19, 2024 | alzres.biomedcentral.com | Université Paris-Cité |Brain Disorders

Demographics and characteristics are illustrated in Table 1. A total of 320 participants were enrolled in the study including 158 patients with AD, 32 with FTD, 30 with DLB, 59 patients with NND and 41 individuals with SCD. Overall, 220 patients (68.7%) were diagnosed with a cognitive decline due to a neurodegenerative disease at various severity (AD, FTD, or DLB).

Oct 18, 2024 | link.springer.com | Université Paris-Cité |Brain Disorders

AbstractAnalysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well as longitudinal cognitive decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice.

Sep 25, 2024 | alzres.biomedcentral.com | Sahlgrenska Academy |Brain Disorders

ReferencesSelkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25years. EMBO Mol Med. 2016;8(6):595–608. CAS  PubMed  PubMed Central  Google Scholar  Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3(1):1. PubMed  PubMed Central  Google Scholar  Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al.

Jun 9, 2024 | link.springer.com | Brain Disorders

AbstractΒ-site amyloid precursor protein (APP) cleaving enzyme (BACE1) is a crucial protease in the production of amyloid-β (Aβ) in Alzheimer’s disease (AD) patients. However, the side effects observed in clinical trials of BACE1 inhibitors, including reduction in brain volume and cognitive worsening, suggest that the exact role of BACE1 in AD pathology is not fully understood.

Apr 25, 2024 | link.springer.com | Region Västra Götaland |Brain Disorders

AbstractInsidious disability worsening is a common feature in relapsing–remitting multiple sclerosis (RRMS). Many patients experience progression independent of relapse activity (PIRA) despite being treated with high efficacy disease-modifying therapies. We prospectively investigated associations of body-fluid and imaging biomarkers with PIRA. Patients with early RRMS (n = 104) were prospectively included and followed up for 60 months. All patients were newly diagnosed and previously untreated.